ChiCTR2300075156: Phase I clinical study on tolerability, safety, and efficacy of Dalpiciclib combined with Apatinib in the treatment of patients with advanced or metastatic sarcoma |
|
|
| Not yet recruiting | 1 | 9 | | Dalpiciclib 100mg once daily oral d1-21+Apatinib 250mg once daily oral d1-28, every 28 days as one cycle; ;Dalpiciclib 100mg once daily oral d1-21+Apatinib 500mg once daily oral d1-28, every 28 days as one cycle; ;Dalpiciclib 150mg once daily oral d1-21+Apatinib 500mg once daily oral d1-28, every 28 days as one cycle; | Peking University Third Hospital; Peking University Third Hospital, Self-fding | Sarcoma | | | | |